Updated 9MW2821 data support Nectin-4 as a target in cervical cancer, but Mabwell must prove that early response and survival signals outperform established ADC and immunotherapy options.
Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Mabwell doses first patient in Phase II trial of IL-11 antibody for pathological scarring. Find out what this means for fibrosis drug development.
Mabwell Biopharmaceuticals has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration to initiate a Phase IIa clinical study for its anti-ST2 monoclonal antibody, 9MW1911, in patients with moderate-to-severe chronic obstructive pulmonary disease. This regulatory milestone comes on the heels of a completed Phase IIa study in China, where Mabwell